352 related articles for article (PubMed ID: 22310590)
1. Safety and efficacy of generic cyclosporine arpimune in Filipino low-risk primary kidney transplant recipients.
Pamugas GE; Danguilan RA; Lamban AB; Mangati VB; Ona ET
Transplant Proc; 2012 Jan; 44(1):101-8. PubMed ID: 22310590
[TBL] [Abstract][Full Text] [Related]
2. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience.
Santos SM; Carlos CM; Cabanayan-Casasola CB; Danguilan RA
Transplant Proc; 2012 Jan; 44(1):154-60. PubMed ID: 22310603
[TBL] [Abstract][Full Text] [Related]
3. Comparison of generic cyclosporine microemulsion versus neoral in de novo renal transplant recipients managed by 2-hour postdose monitoring.
Sharma A; Shekhar C; Heer M; Minz M
Transplant Proc; 2006 Sep; 38(7):2051-3. PubMed ID: 16979996
[TBL] [Abstract][Full Text] [Related]
4. Cyclosporine microemulsion formulation (sigmasporin microral) effect as first-line immunosuppressant on renal functions at 3 years.
Al Wakeel J; Shaheen FA; Al Alfi A; Abbas Fagir EH; Iman A; Nampoory MR; Al Mousawi MS; Said T; Abou Zeinab H; Shaker DS; Ghaedi BB
Transplant Proc; 2012 Jan; 44(1):94-100. PubMed ID: 22310589
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion.
Thervet E; Pfeffer P; Scolari MP; Toselli L; Pallardó LM; Chadban S; Pilmore H; Connolly J; Buchler M; Schena FP; Carreño CA; Dandavino R; Cole E
Transplantation; 2003 Sep; 76(6):903-8. PubMed ID: 14508352
[TBL] [Abstract][Full Text] [Related]
6. [A comparative randomized prospective multicenter study of Sandimmune vs Neoral in liver transplantation].
Roy A; Grant DR; Kneteman NM; Tchervenkov JI; Levy GA; Tan A; Hendricks L
Ann Chir; 1998; 52(8):716-21. PubMed ID: 9846420
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of changing from cyclosporine C0 to C2 monitoring in stable recipients following renal transplantation: a prospective cohort study.
Zhang Y; Zhang XD; Wang Y
Transplant Proc; 2011 Dec; 43(10):3697-701. PubMed ID: 22172829
[TBL] [Abstract][Full Text] [Related]
8. Safe conversion to cicloral, a generic cylosporine, in both stable and de novo renal transplant recipients.
Kahn D; Muller E; Pascoe M
Saudi J Kidney Dis Transpl; 2010 May; 21(3):426-32. PubMed ID: 20427863
[TBL] [Abstract][Full Text] [Related]
9. Graft function based on two hours peak level monitoring of cyclosporine A during the first six months of renal transplantation.
Hami M; Naghibi M; Mojahedi MJ; Sharifipour F; Shakeri MT
Saudi J Kidney Dis Transpl; 2012 Nov; 23(6):1169-74. PubMed ID: 23168844
[TBL] [Abstract][Full Text] [Related]
10. The clinical impact of 1:1 conversion from Neoral to a generic cyclosporine (Gengraf) in renal transplant recipients with stable graft function.
Qazi YA; Forrest A; Tornatore K; Venuto RC
Clin Transplant; 2006; 20(3):313-7. PubMed ID: 16824147
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the bioequivalence of a generic cyclosporine A by a randomized controlled trial in stable renal recipients.
Hibberd AD; Trevillian PR; Roger SD; Wlodarczyk JH; Stein AM; Bohringer EG; Milson-Hawke SM
Transplantation; 2006 Mar; 81(5):711-7. PubMed ID: 16534473
[TBL] [Abstract][Full Text] [Related]
12. Single-center experience with tacrolimus versus cyclosporine-Neoral in renal transplant recipients.
Boots JM; van Duijnhoven EM; Christiaans MH; Nieman FH; van Suylen RJ; van Hooff JP
Transpl Int; 2001 Dec; 14(6):370-83. PubMed ID: 11793034
[TBL] [Abstract][Full Text] [Related]
13. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
[TBL] [Abstract][Full Text] [Related]
14. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
[TBL] [Abstract][Full Text] [Related]
15. Abbreviated AUC monitoring of cyclosporine more adequately identified patients at risk for acute rejection during induction of immunosuppressive therapy after kidney transplantation than recommended C2 concentration values.
Troncoso P; Ortiz AM; Jara A; Vilches S
Transplant Proc; 2009; 41(1):127-30. PubMed ID: 19249495
[TBL] [Abstract][Full Text] [Related]
16. Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy.
Cantarovich M; Besner JG; Barkun JS; Elstein E; Loertscher R
Clin Transplant; 1998 Jun; 12(3):243-9. PubMed ID: 9642517
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic, hemodynamic, and metabolic effects of cyclosporine sandimmune versus the microemulsion neoral in heart transplant recipients.
White M; Pelletier GB; Tan A; Jesina C; Carrier M
J Heart Lung Transplant; 1997 Aug; 16(8):787-94. PubMed ID: 9286770
[TBL] [Abstract][Full Text] [Related]
18. One-Year Multicenter Double-Blind Randomized Clinical Trial on the Efficacy and Safety of Generic Cyclosporine (Iminoral) in De Novo Kidney Transplant Recipients.
Khatami SM; Taheri S; Azmandian J; Sagheb MM; Nazemian F; Razeghi E; Shahidi S; Sadri F; Shamshiri AR; Sayyah M
Exp Clin Transplant; 2015 Jun; 13(3):233-8. PubMed ID: 26086833
[TBL] [Abstract][Full Text] [Related]
19. Six-month clinical outcome of cyclosporine microemulsion formulation (Sigmasporin Microral) in stable renal transplant patients previously maintained on sandimmun neoral.
Al Wakeel JS; Shaheen FA; Mathew MC; Abou Zeinab HM; Al Alfi A; Tarif NM; Al Mousawi MS; Mahmoud TS; Alorrayed AS; Fagir EA; Dham RS; Shaker DS
Transplant Proc; 2008 Sep; 40(7):2245-51. PubMed ID: 18790205
[TBL] [Abstract][Full Text] [Related]
20. Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. International Sandimmun Neoral Study Group.
Keown P; Niese D
Kidney Int; 1998 Sep; 54(3):938-44. PubMed ID: 9734620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]